Thermal Clients Formation Bio and Georgiamune Named to Fierce Biotech's 2025 Fierce 15
Thermal is proud to announce that clients Formation Bio and Georgiamune have been recognized as two of ...
Jennifer Doudna on CRISPR's Next Frontier: From Rare Disease Breakthroughs to Agricultural Innovation
Nobel Laureate discusses groundbreaking baby KJ case, sickle cell progress, and the future of gene editing at ...
Thermal Clients Featured in WSJ Longevity Investment Deep Dive
Wall Street Journal spotlights the billionaire-backed longevity sector in a comprehensive analysis—featuring two Thermal clients at the center of the boom.
Retro ...
New Center Aims to Scale Personalized CRISPR Cures for Children with Rare Genetic Diseases
Bloomberg covers the launch of the Center for Pediatric CRISPR Cures - a $20M initiative that ...
...Tweaking proteins to do human bidding is nothing new. Enzymes and antibodies, for example, have long endured such outrages. But that is not what Dr Ennist is up to. ...
AI drug discovery and development companies have emerged as one of the hottest areas of the wide-ranging life sciences industry.
Why it matters: As AI-focused biotechs proliferate, VC investors and ...
In 2010, the world of cancer treatment witnessed something remarkable. A new class of drugs called immune checkpoint inhibitors showed unprecedented results in cancers that had long defied treatment. By unleashing ...
During a visit to Lawrence Berkeley National Laboratory (Berkeley Lab), Secretary of Energy Chris Wright today announced a new contract with Dell Technologies to develop NERSC-10, the next flagship ...
The technique used on a 9½-month-old boy with a rare condition has the potential to help people with thousands of other uncommon genetic diseases.
Something was very wrong with Kyle ...
Demis Hassabis is reshaping what’s possible in science. His work at DeepMind—most notably the development of AlphaFold, which earned him a share of the 2024 Nobel Prize in Chemistry—is ...
In early 2005 Rodolphe Barrangou and Philippe Horvath were staring at some very odd bits of repeating genetic code on a computer screen in France. The sequences came from ...
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials ...
Roche’s exercise of its option concludes initial collaboration and further validates Dyno’s field-leading gene delivery platform and AI-powered sequence design technologies for therapeutic developers
Dyno to receive ...
Genesis Therapeutics started in now-a16z venture capitalist Vijay Pande’s lab at Stanford, where Genesis co-founder and CEO Evan Feinberg did his Ph.D. A16z led Genesis’ 2023 $200 million series B alongside ...
The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome ...
Company’s first offering, Ataraxis Breast, clinically validated in landmark study to be 30% more accurate than the current standard of care for breast cancer
$4 million in seed ...
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG is willing to pay more than $1 billion to solve one ...
New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
Dyno to receive US$50 million upfront cash ...
The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow organs for people in need—but experts are also concerned about ...
Four years ago, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize in chemistry for the development of a method for genome editing called CRISPR-Cas9.
In her lecture, Doudna detailed “extraordinary and exciting opportunities” for the technology ...
How do we develop and integrate breakthrough health technology into our lives?
From robot helpers to smart prosthetics to "smart skin" to CRISPR gene editing, our ability to build a ...
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by ...
Prof Jennifer Doudna, the ‘Godmother of Crispr’, says ‘figuring out how to edit the brain is probably coming in the next decade’.
Jennifer Doudna says she is an “unlikely success ...
Why Jennifer Doudna is one of Fast Company’s 10 most innovative people of the last 10 years
Doudna codeveloped the revolutionary gene-editing technology known as CRISPR-Cas9. Now it’s leading to ...
"Reengineering Life: The Next Frontiers in Science" is Fareed Zakaria GPS's special report on CNN profiling Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna and the development, rise, ...
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems ...
Parag Mallick, founder and chief scientist of Nautilus Biotechnology, hopes his company’s solutions will unlock the secrets of proteins, the building blocks of biology. Being a magician as well, ...
New advancements in artificial intelligence have the capacity to deliver major breakthroughs in cancer therapy.
AI-powered protein design company Profluent used AI to make an open-source gene editor called OpenCRISPR-1.
OpenCRISPR-1 ...
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.
To read of AI’s feats in ...
Late blight is an old foe of humans. This disease catalysed the devastating Irish potato famine that began in 1845.
It is caused by a fungus-like pathogen, which quickly kills ...
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value.
As hay fever season arrives, once again, for allergy and asthma ...
Much as ChatGPT generates poetry, a new A.I. system devises blueprints for microscopic mechanisms that can edit your DNA.
Generative A.I. technologies can write poetry and computer programs or create images of teddy ...
The most striking evidence that artificial intelligence can provide profound scientific breakthroughs came with the unveiling of a program called AlphaFold by Google DeepMind.
In 2016 researchers at the company ...
As OpenAI's CEO, Altman is widely considered to be the face of artificial intelligence, reprogramming the way we'll live and work for years to come. His relentless push into ...
Funding propels company’s proprietary platform consisting of Generative AI models and large-scale datasets purpose-built for designing and validating novel proteins, opening new frontiers in therapeutics and industrial applications
...
Expanding medical therapies based on Crispr gene-editing globally is “unrealistic” and the sector needs heavy investment to make the technology, which could transform treatment of diseases, accessible to all, ...
Venture capitalists are financing drugmakers seeking to improve upon today’s blockbuster weight-loss medications or combat their side effects.
New obesity medications have helped millions of people lose weight but can ...
Around 10 million. That’s the number of lives forecasters believe we will lose each year by 2050 as bacteria develop defenses against the drugs we use to fight infections.
Tackling antibiotic resistance, though, ...
BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the hottest areas in obesity ...
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline
Azelaprag improves metabolic and muscle ...
